The optimal management of people with osteosarcoma who are older than 50 years, including the impact of neoadjuvant chemotherapy, is not well documented. This study assessed characteristics and outcomes of patients with osteosarcoma in this age cohort using retrospective data from 19 centers in the French sarcoma network (RESOS and NetSarc).
A total of 117 patients with osteosarcoma who were treated between January 2000 and May 2015 were identified. Their median age was 63 years (range, 51-84 years). Most were male (51%) with a good performance status (65%). The most common primary tumor locations were limbs (40%), skull or face (18%), and pelvis (13%).
Half of these older patients with osteosarcoma received neoadjuvant chemotherapy (51%). Chemotherapy recipients were relatively younger (P <0.0001) and had less unplanned initial treatment (P = 0.011). Only 29% achieved a good histologic response.
Overall survival rates at 2 and 5 years were 58% for the whole cohort of older patients, 62% for those with localized osteosarcoma, and 38% for those with metastatic osteosarcoma. Researchers concluded that patients with osteosarcoma who are older than 50 years had poor clinical outcomes, suggesting a high unmet need for more effective and tolerable therapies.
Boudou-Rouquette P, et al. CTOS 2016. Abstract 2554555. Poster 111.